Clinical trials: Dementia Alzheimers
Alzheimer Disease
P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid
This research will be achieved by the assessment of p75NTR-ECD expression (total and linked to different species of Aβ (Aβ1-40 and Aβ-1-42)) within the cerebrospinal fluid (CSF) of patients with AD dementia, mild cognitive…
- Trial name
- P75NTR-MND (NCT02946710)
- Testing
- cerebrospinal fluid
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Toulouse
Alzheimer Disease, Alzheimer Dementia
Alzheimer's Caregiver Coping: Mental and Physical Health
This study evaluates the effectiveness of Behavioral Activation (BA) therapy vs Support and Information for reducing risk for emotional and cardiovascular diseases in Alzheimer's caregivers.
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Alzheimer's Disease, Dementia
- Trial name
- NCT02317523
- Testing
- Behavioral Activation, Information and Support
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- University of California, San Diego
Dementia, Alzheimer Disease
Digital Interventions in Neuro-Rehabilitation: Gotcha!
Aims and background Everyone forgets the names of people they should know at times. Having dementia makes this problem worse. People with dementia have told expressed they forget the names of people they care about and this can…
- Conditions
- Dementia, Alzheimer Disease, Anomia
- Trial name
- NCT04570215
- Testing
- Gotcha! Therapy application, Gotcha Therapy application: Maintenance
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Sedentary Lifestyle, Stress, Psychological
Development of An Exergame for Caregivers of Individuals With Alzheimer's Disease or Related Dementias
The study goal is to evaluate user experience with our developed exergame, which was designed to increase physical activity, exercise self-efficacy, and social connections among caregivers of individuals with Alzheimer's disease…
- Trial name
- NCT03124550
- Testing
- Exergame Experience
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Brandeis University
Alzheimer's Disease
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
The investigators intend to perform exploratory evaluation of the treatment effectiveness and safety of PM012 Tablet of PuriMED Co., Ltd. at 2 doses in Korean patients with mild to moderate dementia of Alzheimer's type.
- Trial name
- ADD (NCT01715350)
- Testing
- PM012
- Where
- 4 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- VTBIO Co. LTD
Alzheimer Disease
Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides
This is a Phase I, open label, randomized, 6-way crossover, pilot PK study
- Trial name
- NCT03635879
- Testing
- MCTprocal medical food, Milk/tricaprilin oil blend, AC-1207
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cerecin
Alzheimer's Disease
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo.
- Trial name
- NCT01193608
- Testing
- AAB-003 (PF-05236812)
- Where
- 29 sites in United States, South Korea
- Volunteers
- 88 people
- Sponsor
- Pfizer
Healthy
Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population
To assess the safety and tolerability of ascending, multiple, oral doses of GSI-953 in healthy elderly subjects.
- Trial name
- NCT00547560
- Testing
- GSI-953
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Memory Disorders, Cognitive Impairment
Brain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention
The purpose of this research is to determine if training in memory support aids and healthy lifestyle activities (physical exercise, mentally stimulating activities and stress management) can have a positive effect on memory…
- Trial name
- BB2 (NCT05027789)
- Testing
- Self-Guided, Structured Group
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- University of California, Davis
Alzheimer Disease
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.
The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with Alzheimer's disease, and…
- Trial name
- NCT00301574
- Testing
- galantamine
- Volunteers
- 398 people
- Sponsor
- Janssen Pharmaceutical K.K.
Dementia, Alzheimer Disease
Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects
Capturing the earliest stages of Dementia especially Alzheimer's Disease (AD) is a great challenge. Until now the NINCDS-ADRDA and the DSM criteria for AD were largely used as diagnostic standards in research.
- Trial name
- AMIMAGE (NCT00951197)
- Testing
- Neuroimaging
- Where
- France
- Volunteers
- 318 people
- Sponsor
- University Hospital, Bordeaux
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT04141150
- Testing
- [18F]APN-1607
- Where
- 3 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics, LLC
Alzheimer Disease, Cognitive Impairment
Multi-Center Study of Sensory Stimulation to Improve Brain Function
The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia Alzheimers
- Trial name
- Overture (NCT03556280)
- Testing
- GammaSense Stimulation System (Active Settings)
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cognito Therapeutics, Inc.
Postoperative Cognitive Dysfunction
Effects of Brain Beta-Amyloid on Postoperative Cognition
Postoperative cognitive decline (POCD) affects up to 50% of non-cardiac surgical patients greater than or equal to 65 years of age.
- Trial name
- NCT01606488
- Testing
- Florbetapir F 18 (18F-AV-45), no intervention
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Francisco
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Dementia, Alzheimer's Disease and Related Dementias
HomeCare Medication Management for People With Dementia
This study will evaluate whether the HomeCare medication management system can improve medication adherence and related outcomes for adults age 65 and older living with dementia, Alzheimer's disease, or related dementias.
- Trial name
- NCT07872072
- Testing
- HomeCare
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- HiDO Technologies
Alzheimer's Disease
Multi-modal Neuroimaging in Alzheimer's Disease
According to estimations, Alzheimer's disease affects approximately 860,000 people aged of more than 65 years in France. This disease is characterized by disorders of cognitive functions, including memory, associated with…
- Trial name
- IMAP (NCT01554202)
- Testing
- assessment of memory, circulating tPA dosage, ApoE4
- Where
- 5 sites in France
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Alzheimer's Disease
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine treatment phase.
- Trial name
- NCT00234637
- Testing
- Rivastigmine, memantine
- Where
- France
- Volunteers
- 204 people
- Sponsor
- Novartis
Alzheimer Disease, Caregiver Stress Syndrome
Learning and Improving Alzheimer's Patient-Caregiver Relationships Via Smart Healthcare Technology
The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships.
- Trial name
- NCT04536701
- Testing
- Mood Monitoring and Behavioral Recommendation System
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Mild to Moderate Alzheimer's Disease
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ROBIN (NCT01039701)
- Testing
- AZD1446
- Where
- 12 sites in Czechia, Hungary and 1 more
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.